• 응용통계연구
• /
• 제26권4호
• /
• pp.581-594
• /
• 2013

집단축차설계법은 중간분석을 실시하여 임상시험용 의약품의 유효성 또는 무용성이 조기에 발견되면 임상시험을 조기에 종료할 수 있는 시험설계법이다. 적응적 설계법은 중간분석 결과를 이용하여 시험설계를 변경하거나, 확률적으로 독립인 두개의 임상시험 결과를 결합하는 등 다양한 적응법으로 임상시험의 설계를 수정할 수 있는 시험설계법이다. 집단축차설계법과 적응적 설계법에서 주요하게 고려할 점은, 시험 전체적으로 제1종 오류를 적절히 분배하고 통제하여 임상시험 전체의 일관성을 유지하도록 하는 것이다. 반복측정자료 또는 경시적자료의 통계적 모형이 고려되는 경우에는 통계적 추론이 더욱 복잡하고 어려워진다. Lee 등 (2002)에서는 반복측정치를 가지는 임상시험에서 집단축차설계에서 미리 정한 기준에 의하여 임상시험이 종료된 후, 독립증분과 단계적 순서관계를 고려한 신뢰구간 추정법을 제안한 바 있다. 본 연구는 Lee 등 (2002)를 적응적 설계로 확장하였다. 적응법을 실시한 전과 후의 임상시험을 확률적으로 독립인 관계로 정의하는 검정통계량을 유도하여 적응적 집단축차검정법이 가능하게 하였다. 또한, 임상시험이 종료된 후 단계적 순서관계를 고려한 신뢰구간 추정법을 제안하였으며, 모의실험을 통하여 그 안정성을 확인하였다.

• 한국의료윤리학회지
• /
• 제21권4호
• /
• pp.344-359
• /
• 2018

본 연구에서는 임상시험에 참여한 만성신장질환자를 대상으로 임상시험 설명문 및 동의서 이해도와 관련 요인을 파악하기 위한 서술적 조사 연구이다. 자료수집은 임상시험에 참여하는 만성신장질환자 85명을 대상으로 2017년 7월 1일부터 2018년 4월 30일까지 설문조사를 통해 실시하였다. 본 연구의 결과로 설명문 및 동의서 객관적 이해도의 평균은 100점 만점에 69.56점, 주관적 이해도의 평균은 5점 만점에 3.28점으로 나타났다. 임상시험 설명문 및 동의서 객관적 이해도의 관련요인으로는 참여 동기(F=13.603, p<.001), 동의서 보유 유무(F=-4.833, p<.001), 건강문해력(F=27.709, p<.001)으로 나타났다. 주관적 이해도의 관련요인으로는 참여 동기(F=5.542, p<.002), 추가정보(F=-3.095, p<.003), 질문(F=-3.399, p<.001), 동의서 보유 유무(F=-5.712, p<.001), 건강문해력(F=5.941, p<.001)으로 나타났다. 결론적으로 만성질환자의 임상시험 이해도는 국외의 연구에 비해 이해도가 낮은 수준이며, 설명문 및 동의서의 내용을 일방적으로 전달하기보다는 이해도와 관련된 요인을 고려하여 동의과정에서 대상자의 충분한 이해를 도울 수 있도록 노력이 필요할 것으로 생각된다.

• Journal of Genetic Medicine
• /
• 제8권1호
• /
• pp.28-34
• /
• 2011

대부분의 의사들은 임상시험을 치료약제개발 후 의료현장에서 사용하기 위해 진행되는 과정으로 생각할 것이다. 실험실에서 개발된 기술이 진단검사로써 도입되기 위해서는 치료약제의 경우와 유사한 임상시험 과정을 거쳐 그 안정성과 유효성에 대한 검증을 필요로 한다. 치료약제의 효과검증에서 가장 우수한 근거를 얻을 수 있는 연구방법은 무작위대조연구 방법이지만, 이를 검체진단검사에 그대로 적용하기는 어렵다. 검체진단검사의 경우 비교연구가 진단정확도의 검증을 위해 현실적으로 사용할 수 있는 연구방법이지만 대상군의 모집 방법과 구분 방법, 질환대상자의 질환 심각도, 참고표준의 선택과 적용, 눈가림 여부 등 여러 요인들이 진단정확도 지표에 직접적인 영향을 주기 때문에, 좋은 근거수준의 연구결과를 얻기 위해서는 이러한 요소들을 고려한 잘 고안된 연구디자인이 중요하다. 또한 검체진단검사는 치료약제의 경우와 달리 결과를 얻기 위한 검사과정이 사용자인 일선 검사실에 의해 계속 생산되어야 하고, 검사의 개발과 발전의 속도가 빠르며, 일선검사실이 최종사용자이자 개발자인 경우가 흔하다는 특성이 있다. 저자들은 이러한 검사의 특성을 고려하여 검사법 자체의 수행능력에 대한 검증으로부터 검사법 성능평가를 위한 질환확진군과 정상군에 대한 비교연구, 일련의 질환의심자 대상의 진단정확도 평가와 임상 효과성 평가, 도입 후 일상감시로 이어지는 임상시험의 진행단계를 제안하고자 한다.

• 한국인터넷방송통신학회논문지
• /
• 제17권5호
• /
• pp.137-142
• /
• 2017

인구의 고령화와 의료서비스 수요의 증가로 한의학의 이론을 기초로 한 의료기기 개발이 증가하고 있다. 개발한 의료기기의 임상적 유효성 확보를 위한 다양한 임상시험들이 수행되고 있으며, 이 과정에서 다양하게 수집되는 정보들의 체계적인 관리의 중요성이 증가하고 있다. 본 논문에서는 한의학의 대표적인 진단 방법인 맥진을 기기화 한 맥진기를 이용하여 임상시험을 진행하는데 있어 환자의 의학적 정보, 맥진기의 측정 정보들을 체계적으로 관리할 수 있는 데이터베이스를 설계하고 구축하였다. 구축된 데이터베이스는 임상시험에 대한 다양한 정보 및 측정된 정보의 질관리를 통해 기존 알고리즘 검증 또는 새로운 알고리즘 개발 시 효율적인 대응이 가능하고, 임상 데이터의 통제 측면에서도 여러 장점들을 가지고 있다. 본 연구의 결과는 이종의 맥진기나 다른 생체신호 측정기와의 정보 공유가 가능한 통합 데이터베이스 관리 시스템 구축을 위한 한의 의료기기 데이터 표준안 구성에 기여할 수 있을 것이다.

• 한방재활의학과학회지
• /
• 제27권2호
• /
• pp.39-54
• /
• 2017

Objectives This study aimed to search the Chinese literature on acupotomy for lumbar disc herniation and to analyze their methodologies. Methods Using 4 Chinese databases (CBM [www.sinomed.ac.cn], CNKI [www.cnki.net], WANFANG [www.wanfangdata.com], and WEIPU [www.cqvip.com]), we searched for clinical trials conducted in China over the past 10 years on acupotomy for lumbar disc herniation. The search terms used were "(腰椎椎間板脫出症 or 椎間板脫出症 or 椎間板脫出) and (针刀or 针刀松解术)" and we selected only meta-analyses that were published before December 2016. From among these meta-analyses, we excluded duplicates and selected the remaining 36 randomized controlled trials (RCTs) for our final analysis. Results The largest numbers of acupotomy papers were published in 2008 and 2013 (8 papers each). The average number of subjects was 120; the most common treatment method used for the control group was standard acupuncture (in 11 papers), and the most common concurrent treatment in the treatment group was massage (in 10 papers). The most common site of needle insertion was between the spinous processes, or at less than 0.5 cm on either side of the spinous processes (in 24 papers). The most common site of adhesion lysis was at the transverse process (in 24 papers). Two studies were blinded, and the mean Jadad score was 1.17. Conclusions A large number of RCTs on the use of acupotomy for lumbar disc herniation are conducted every year in China, and the procedure has been shown to be very effective, with few adverse effects. However, the average quality of the studies was not very high. Based on our study, we expect several high-quality clinical trials on acupotomy to be conducted in Korea in the future.

• Biomolecules & Therapeutics
• /
• 제28권1호
• /
• pp.34-44
• /
• 2020

Mesenchymal stem cells (MSCs) have been proposed as an alternative therapy to be applied into several pathologies of the nervous system. These cells can be obtained from adipose tissue, umbilical cord blood and bone marrow, among other tissues, and have remarkable therapeutic properties. MSCs can be isolated with high yield, which adds to their ability to differentiate into non-mesodermal cell types including neuronal lineage both in vivo and in vitro. They are able to restore damaged neural tissue, thus being suitable for the treatment of neural injuries, and possess immunosuppressive activity, which may be useful for the treatment of neurological disorders of inflammatory etiology. Although the long-term safety of MSC-based therapies remains unclear, a large amount of both pre-clinical and clinical trials have shown functional improvements in animal models of nervous system diseases following transplantation of MSCs. In fact, there are several ongoing clinical trials evaluating the possible benefits this cell-based therapy could provide to patients with neurological damage, as well as their clinical limitations. In this review we focus on the potential of MSCs as a therapeutic tool to treat neurological disorders, summarizing the state of the art of this topic and the most recent clinical studies.

• 대한이식학회지
• /
• 제31권4호
• /
• pp.157-169
• /
• 2017

Regulatory T cells (Treg) naturally rein in immune attacks, and they can inhibit rejection of transplanted organs and even reverse the progression of autoimmune diseases in mice. The initial safety trials of Treg against graft-versus-host disease (GVHD) provided evidence that the adoptive transfer of Treg is safe and capable of limiting disease progression. Supported by such evidence, numerous clinical trials have been actively investigating the efficacy of Treg targeting autoimmune diseases, type I diabetes, and organ transplant rejection, including kidney and liver. The limited quantity of Treg cells harvested from peripheral blood and subsequent in vitro culture have posed a great challenge to large-scale clinical application of Treg; nevertheless, the concept of CAR (chimeric antigen receptor)-Treg has emerged as a potential resolution to the problem. Recently, two CAR-T therapies, tisagenlecleucel and axicabtagene ciloleucel, were approved by the US FDA for the treatment of refractory or recurrent acute lymhoblastic leukemia. This approval could serve as a guideline for the production protocols for other genetically engineered T cells for clinical use as well. The phase I and II clinical trials of these agents has demonstrated that genetically engineered and antigen-targeting T cells are safe and efficacious in humans. In conclusion, both the promising results of Treg cell therapy from the clinical studies and the recent FDA approval of CAR-T therapies are paving the way for CAR-Treg therapy in clinical use.

• 대한예방한의학회지
• /
• 제28권1호
• /
• pp.119-130
• /
• 2024

Objectives : The objective of this review is to examine the variety of evaluation parameters utilized in clinical trials that assess the anticancer efficacy of herbal medicine, focusing on the importance of including both symptomatic management and direct anticancer effectiveness. Methods : A detailed literature review was conducted across PubMed, Embase, and the Cochrane Library to identify clinical trials investigating the antitumor efficacy of herbal medicine. The search was performed on February 22, 2024. This review specifically examined the employed outcome measures, which were then categorized and analyzed to understand their relevance and application in evaluating the anticancer properties of herbal medicine. Results : From an initial search of 900 records, 15 clinical trials were selected for in-depth analysis after deduplication and screening. These studies evaluated the efficacy of herbal medicine across various cancers, including hepatocellular carcinoma, colorectal cancer, and breast cancer, using outcome measures such as survival rates, disease control rates, and quality of life improvements. The research spanned multiple countries, primarily in East Asia and the United States, reflecting a global interest in herbal medicine as a complementary approach to cancer treatment. The present study demonstrated that herbal medicine, especially when used alongside standard treatments, potentially improved clinical outcomes and patient well-being. Conclusions : The findings of this review highlight the need for a broader focus on the full range of therapeutic capabilities of herbal medicine, including its direct anticancer effects, in the management of cancer patients. Future oncology research involving herbal medicine should integrate a wide spectrum of clinical endpoints to fully ascertain its impact on cancer treatment and patient health.

• 대한암한의학회지
• /
• 제21권2호
• /
• pp.51-61
• /
• 2016

Background : Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect in cancer patients who were exposed to chemotherapy. CIPN impacts on the quality of life and could delay chemotherapy. The aim of this review was to assess the therapeutic effectiveness of herbal medicine in CIPN patients. Methods : Randomized controlled trials (RCTs) were included in this review. We searched MEDLINE, Cochrane database, EMBASE, CNKI, Wanfang and four Korean databases without restrictions on time or language. The risk of bias was assessed using the Cochrane risk of bias tool. Results : Eleven RCTs involving 706 patients met the inclusion criteria. Eleven different herbal medicines were examined in the included trials. Almost RCTs showed insufficiency in the reporting randomization method and allocation concealment. One trial used allocation concealment and a double-blinding method. Five studies reported that participants dropped out of RCTs and conducted an 'as-treated analysis'. One trials reported adverse effects of herbal medicine. In ten of the eleven trials, the use of herbal medicine had shown significant differences in clinical symptoms or nerve conduction velocity. Conclusions : The use of herbal medicines for CIPN showed significant improvements in the management of CIPN. However, conclusions cannot be drawn because of the generally low quality of methodology and low quantity of data for each single herbal medicine. Further rigorous trials are needed.

• Tuberculosis and Respiratory Diseases
• /
• 제77권3호
• /
• pp.105-110
• /
• 2014

Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is an important cause of morbidity and mortality. The aim of this review is to summarize the findings from clinically important publications over the last year in the area of VTE. In this review, we discuss 11 randomized controlled trials published from March 2013 to April 2014. The COAG and the EU-PACT trials indicate that pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or marginal usefulness in the Caucasian population. Recent clinical trials with novel oral anticoagulants (NOACs) have demonstrated that the efficacy and safety of rivaroxaban, apixaban, edoxaban, and dabigatran are not inferior to those of conventional anticoagulants for the treatment of VTE. The PEITHO and ULTIMA trials suggested that rescue thrombolysis or catheter-directed thrombolysis may maximize the clinical benefits and minimize the bleeding risk. Lastly, riociguat has a proven efficacy in treating chronic thromboembolic pulmonary hypertension. In the future, NOACs, riociguat, and catheter-directed thrombolysis have the potential to revolutionize the management of patients with VTE.